| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Collaboration revenue | ||||||
43,103 | 30,434 | 26,117 | 16,479 | 6,044 | ||
Operating expenses: | ||||||
Research and development | ||||||
108,413 | 89,115 | 67,647 | 31,840 | 11,170 | ||
General and administrative | ||||||
41,058 | 32,189 | 28,025 | 16,798 | 8,283 | ||
Total operating expenses | ||||||
149,471 | 121,304 | 95,672 | 48,638 | 19,453 | ||
Operating loss | ||||||
-106,368 | -90,870 | -69,555 | -32,159 | -13,409 | ||
Interest income | ||||||
6,835 | 5,527 | 2,012 | 525 | - | ||
Loss before income taxes | ||||||
- | - | - | - | -13,409 | ||
Income tax benefit | ||||||
- | - | - | - | -1,012 | ||
Net loss | ||||||
-99,533 | -85,343 | -67,543 | -31,634 | -12,397 | ||
Net loss per share, basic and diluted | ||||||
-2.11 | -1.98 | -1.88 | -1.42 | -51.02 | ||
Weighted average shares outstanding, basic and diluted | ||||||
47,247 | 43,069 | 36,006 | 22,222 | 243 | ||
Other comprehensive loss: | ||||||
Unrealized gain on marketable securities | ||||||
289 | -28 | - | - | - | ||
Comprehensive loss | ||||||
-99,244 | -85,371 | -67,543 | -31,634 | - | ||